Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.24, Zacks reports.
Spyre Therapeutics Price Performance
NASDAQ:SYRE traded down $0.90 during trading hours on Thursday, reaching $15.07. 128,446 shares of the company were exchanged, compared to its average volume of 622,232. Spyre Therapeutics has a 1-year low of $10.91 and a 1-year high of $40.26. The company has a market capitalization of $908.06 million, a P/E ratio of -4.44 and a beta of 2.82. The business has a 50 day moving average of $16.27 and a 200 day moving average of $17.04.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Spyre Therapeutics stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 18.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,018 shares of the company's stock after acquiring an additional 4,277 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Spyre Therapeutics were worth $442,000 as of its most recent filing with the Securities and Exchange Commission. 80.39% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Separately, Wedbush reaffirmed an "outperform" rating and set a $65.00 target price on shares of Spyre Therapeutics in a report on Wednesday. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Spyre Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $53.40.
Check Out Our Latest Stock Report on Spyre Therapeutics
About Spyre Therapeutics
(
Get Free Report)
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Featured Articles
Before you consider Spyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.
While Spyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
